ACG
<ѻý class="page-description">American College of Gastroenterologyѻý>Selected highlights from the 2024 American College of Gastroenterology annual meeting
Rifaximin also reduced mortality, but its high cost may be a barrier
At scale, the benefits of AI-assisted colonoscopy may not always outweigh the costs
Monoclonal antibody cendakimab also reduced eosinophils compared with placebo
Patients also found MoviPrep to be more tolerable and were more willing to repeat it
The drug also met primary endpoint of reducing peak esophageal intraepithelial eosinophil counts
But conservative management used in most cases
ColoSense test outperforms fecal immunochemical testing in phase III trial
Relationship was seen across the different types of blood thinners
Researchers strongly discourage its use in IBD patients
Most endoscopists reported having back, neck, and hand pain
Disease control also maintained with temporary withdrawal, at least initially
ECOSPOR IV study found low recurrence regardless of the number of prior episodes
U-ENDURE trial also hit co-primary endpoint for endoscopic response
-
AIBD: Advances in Inflammatory Bowel Diseases
December 2024
-
AASLD: American Association for the Study of Liver Diseases
November 2024
-
ACG: American College of Gastroenterology
October 2024
-
EASL: European Association for the Study of the Liver
June 2024